Immunogenicity and Safety of the MF59-adjuvanted Seasonal Influenza Vaccine in Non-elderly Adults: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2025 Jan 8

PMID 39775353

Authors

Alexander Domnich

Carlo-Simone Trombetta

Elettra Fallani

Marco Salvatore

Affiliations

Soon will be listed here.

Abstract

Objective: In Europe, the age indication for the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) has recently been extended from ≥65 to ≥50 years. Considering that the earliest approval of its trivalent formulation (aTIV) in Italy was for people aged ≥12 years, we aimed to systematically appraise data on the immunogenicity, efficacy, and safety of aTIV/aQIV in non-elderly adults.

Methods: A systematic literature review was conducted according to the available guidelines and studies were searched in MEDLINE, Biological Abstracts, Web of Science, Cochrane Library and clinical trial registries. Studies on absolute and relative immunogenicity, efficacy, effectiveness, and safety of aTIV/aQIV in non-elderly adults (<65 years) were potentially eligible. These endpoints were analyzed by virus (sub)types and characteristics of vaccinees. Fixed- and random-effects meta-analyses were performed for data synthesis. Protocol registration: CRD42024512472.

Results: Twenty-four publications were analyzed. aTIV/aQIV was more immunogenic than non-adjuvanted vaccines towards vaccine-like strains: the absolute differences in seroconversion rates were 8.8% (95% CI: 3.7%, 14.0%), 13.1% (95% CI: 6.7%, 19.6%) and 11.7% (95% CI: 7.2%, 16.2%) for A(H1N1), A(H3N2), and B strains, respectively. This immunogenicity advantage was more pronounced in immunosuppressed adults. Additionally, aTIV/aQIV was more immunogenic than non-adjuvanted counterparts towards heterologous A(H3N2) strains with a 10.7% (95% CI: 3.2%, 18.2%) difference in seroconversion rates. Data on antibody persistence and efficacy were limited and inconclusive. Overall, aTIV/aQIV was judged safe and well tolerated, although reactogenic events were more frequent in aTIV/aQIV recipients versus comparators. Serious adverse events were uncommon and no difference (risk ratio 1.02; 95% CI: 0.64, 1.63) between aTIV/aQIV and non-adjuvanted formulations was found.

Conclusions: In non-elderly adults, aTIV/aQIV is safe and generally more immunogenic than non-adjuvanted standard-dose vaccines.

References

Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R . Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol. 2007; 27(5):542-7. DOI: 10.1007/s10875-007-9100-4. View

Fenoglio D, Zocchi M, Parodi A, Durando P, Gabutitp G, Gasparini R . MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. J Prev Med Hyg. 2011; 52(3):137-41. View

Fabbiani M, Sidella L, Corbi M, Martucci R, Sali M, Colafigli M . HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. Vaccine. 2013; 31(28):2914-8. DOI: 10.1016/j.vaccine.2013.04.033. View

Iorio A, Francisci D, Camilloni B, Stagni G, De Martino M, Toneatto D . Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine. 2003; 21(25-26):3629-37. DOI: 10.1016/s0264-410x(03)00408-0. View

Allen J, Ross T . H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018; 14(8):1840-1847. PMC: 6149781. DOI: 10.1080/21645515.2018.1462639. View

Lindert K, Leav B, Heijnen E, Barrett J, Nicolay U . Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. Int J Infect Dis. 2019; 85S:S10-S17. DOI: 10.1016/j.ijid.2019.03.020. View

von Hippel P . The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015; 15:35. PMC: 4410499. DOI: 10.1186/s12874-015-0024-z. View

Cox R . Correlates of protection to influenza virus, where do we go from here?. Hum Vaccin Immunother. 2013; 9(2):405-8. PMC: 3859764. DOI: 10.4161/hv.22908. View

Poder A, Oberije J, Meyer J, Heymer P, Molrine D, Versage E . Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age. Vaccines (Basel). 2023; 11(10). PMC: 10611124. DOI: 10.3390/vaccines11101528. View

10.

Iorio A, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano A . Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine. 2012; 30(9):1617-23. DOI: 10.1016/j.vaccine.2011.12.107. View

11.

Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D . Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2016; 35(4):513-520. DOI: 10.1016/j.vaccine.2016.12.011. View

12.

Belongia E, Simpson M, King J, Sundaram M, Kelley N, Osterholm M . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016; 16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8. View

13.

Kane R, Wang J, Garrard J . Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol. 2007; 60(3):241-9. DOI: 10.1016/j.jclinepi.2006.06.016. View

14.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

15.

Nicolay U, Heijnen E, Nacci P, Patriarca P, Leav B . Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019; 85S:S1-S9. DOI: 10.1016/j.ijid.2019.03.026. View

16.

Domnich A, Panatto D, Pariani E, Napoli C, Chironna M, Manini I . Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults. Int J Infect Dis. 2022; 125:164-169. DOI: 10.1016/j.ijid.2022.10.041. View

17.

Baldo V, Baldovin T, Floreani A, Carraro A, Trivello R . MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine. 2007; 25(20):3955-61. DOI: 10.1016/j.vaccine.2007.02.045. View

18.

Del Giudice G, Hilbert A, Bugarini R, Minutello A, Popova O, Toneatto D . An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006; 24(16):3063-5. DOI: 10.1016/j.vaccine.2006.01.015. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Grohskopf L, Ferdinands J, Blanton L, Broder K, Loehr J . Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024; 73(5):1-25. PMC: 11501009. DOI: 10.15585/mmwr.rr7305a1. View